相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Annual report to the nation on the status of cancer, part I: National cancer statistics
S. Jane Henley et al.
CANCER (2020)
The effect of metformin on the risk of recurrent nonmelanoma skin cancers
Adarsh Ravishankar et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes
Chin-Hsiao Tseng
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Anti-tumor activity of metformin: from metabolic and epigenetic perspectives
Xilan Yu et al.
ONCOTARGET (2017)
Prevalence and Costs of Skin Cancer Treatment in the US, 2002-2006 and 2007-2011
Gery P. Guy et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2015)
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Ulrike Hostalek et al.
DRUGS (2015)
Metformin Inhibits Skin Tumor Promotion in Overweight and Obese Mice
L. Allyson Checkley et al.
CANCER PREVENTION RESEARCH (2014)
Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders
Sara Gandini et al.
CANCER PREVENTION RESEARCH (2014)
Metformin Does Not Affect Cancer Risk: A Cohort Study in the UK Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial
Konstantinos K. Tsilidis et al.
DIABETES CARE (2014)
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Monica Franciosi et al.
PLOS ONE (2013)
Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage
Carolyn Algire et al.
CANCER PREVENTION RESEARCH (2012)
Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
Assiamira Ferrara et al.
DIABETES CARE (2011)
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
DIABETES OBESITY & METABOLISM (2010)
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
P. D. Home et al.
DIABETOLOGIA (2010)
Critical interpretation of Cochran's Q test depends on power and prior assumptions about heterogeneity
Tiago V. Pereira et al.
RESEARCH SYNTHESIS METHODS (2010)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Michael J. Bradburn et al.
STATISTICS IN MEDICINE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): Study design and protocol
PD Home et al.
DIABETOLOGIA (2005)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
A diabetes outcome progression trial (ADOPT)
G Viberti et al.
DIABETES CARE (2002)
分享论文
